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125 mg over 10 minutes, and compared to placebo comprisingSodium ferric gluconate complex in hemodialysis patients:
bacteriostatic saline.Adverse reactions compared to placebo and iron dextran.
Results. A total of 2534 patients were enrolled. The inci-Background. Parenteral iron is often required by hemodial-
dence of drug intolerance (an adverse event precluding re-ysis patients to maintain adequate iron stores. Until recently,
exposure) was significantly less [0.44%, confidence intervalthe only available form of intravenous iron was iron dextran,
(CI) 0.21 to 0.71%] after SFGC as compared to the iron dextranwhich is associated with significant adverse reactions, including
control (2.47%, CI 1.87 to 3.07%, P 0.0001), but higher thananaphylaxis and death. Sodium ferric gluconate complex (SFGC)
after placebo (0.1%, P  0.02). There was no difference foundwas recently approved for use in the U.S. under FDA’s priority
between SFGC and placebo in serious adverse events. A singledrug review. This Phase IV study was designed to evaluate the
life-threatening event occurred after SFGC (0.04%, CI 0.00 tosafety of a single dose of intravenous SFGC as compared to pla-
cebo and a historical iron dextran control. 0.22%), which was significantly less than following iron dextran
Methods. This multicenter, crossover, randomized, double (0.61%, CI 0.36 to 0.86%), P  0.0001.
blind, placebo-controlled prospective comparative study was Conclusion. SFGC is well tolerated when given by intrave-
performed in hemodialysis patients requiring at least 125 mg nous push without a test dose. SFGC has a significantly lower
of elemental iron. The historical control was obtained from a incidence of drug intolerance and life-threatening events as
meta-analysis of four publications examining outcomes in pa- compared to previous studies using iron dextran. The routine
tients exposed to iron dextran. SFGC naı¨ve patients were ad- use of iron dextran in hemodialysis patients should be discon-
ministered SFGC without a test dose, undiluted, at a rate of tinued.
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past five years appear to be due in part to the more risks in special sub-populations, or gather longer term
safety information [21, 22]. Twelve of the last 20 (60%)widespread use of parenteral iron [6]. The use of paren-
teral iron in hemodialysis patients is endorsed by the new agents approved by FDA under the priority review
program were subject to such clinical Phase IV studies,National Kidney Foundation’s Kidney Disease Out-
comes Quality Initiative (K/DOQI) [7]. K/DOQI guide- in contrast to only one of the last 20 (5%) approved
under standard review [21, 22]. Complex design and ethi-lines for anemia management recommend the use of
parenteral iron not only for absolute iron deficiency, but cal issues are involved in Phase IV safety studies, includ-
ing the use of placebo controls to evaluate clinicallyalso for functional iron deficiency, where iron stores are
present but cannot be mobilized rapidly enough to main- available and effective products [23–25]. FDA has not
required placebo controls in most Phase IV safety stud-tain maximal epoetin-driven erythrogenesis [7]. In the
United States (U.S.), the increased use of parenteral iron ies. This could limit rigorous safety evaluation, especially
in patients with concomitant illnesses and poly-phar-has come at a price: the only preparation available until
February 1999, iron dextran, can cause anaphylaxis and macy, which may predispose to adverse experiences. Pla-
cebo controls may be essential for assessment of drugdeath. Life-threatening anaphylactoid reactions occur in
approximately 0.7% of iron dextran treated hemodialysis safety in such patients.
This report describes a novel approach to Phase IVpatients [8], and serious drug intolerance that precludes
further administration occurs in at least 2.5% of patients drug safety evaluation using placebo controls in a single-
dose, crossover study designed to evaluate the safety of a[8–10]. Since 1976 at least 30 deaths in the U.S. have
been attributed to iron dextran use [11]. While a test single dose of intravenous SFGC as compared to placebo
and a historical iron dextran control. This is the largestdose of iron dextran is recommended prior to initiating
full therapy, deaths have occurred subsequent to the test controlled prospective study ever carried out in the he-
modialysis population.dose itself, before a course of iron dextran treatment
[12, 13]. The antigen that induces anaphylaxis in iron
dextran is thought to be the dextran molecule rather
METHODS
than the iron moiety. Dextran is composed of glucose
The study was a multicenter, crossover, randomized,polymers of varying size and its early use, as a volume
double-blind, and prospective, comparative study of theexpander, was associated with anaphylaxis [14]. Alterna-
safety of SFGC in hemodialysis patients. The responsetive intravenous iron preparations, which do not contain
to SFGC was compared to two controls: placebo anddextran, have been used for many years outside of the
a historical control identified from a meta-analysis ofU.S. Sodium ferric gluconate in sucrose injection (so-
publications describing rates of events in patients ex-dium ferric gluconate complex: SFGC) is widely used in
posed to iron dextran formulations. The iron dextranEurope. There have been no reported fatalities due to
control group was not concurrent because of the drug’sSFGC, with a European usage estimated to be similar,
known high adverse event profile, and the paucity ofin terms of total doses administered, as that of iron dex-
iron dextran-naı¨ve patients in the U.S. hemodialysis pop-tran in the U.S. [11]. While hypersensitivity reactions
ulation. The final study design was approved by the FDA.have been anecdotally associated with SFGC, serious
reactions have rarely been reported.
Study objectivesSodium ferric gluconate complex was approved in the
The study had two primary objectives: (a) to compareU.S. in 1999 under the Food and Drug Administration’s
subjectively identified drug intolerance events and life-(FDA’s) priority review program, with a requirement
threatening adverse events after SFGC administrationfor an extensive Phase IV safety analysis. The clinical
to the two controls (concurrent placebo and historicaldata compiled before FDA approval included only 385
iron dextran); and (b) to assess the safety of SFGC whenprospective patient experiences from two controlled
administered by intravenous push at a rate of 12.5 mg/studies and published reports [15–19]. While these data
min. Drug intolerance events were defined as any eventwere supplemented by many years of European clinical
that would preclude further study drug administration.experience in which the incidence of spontaneous ad-
Life-threatening adverse events were defined as any im-verse events was not significant [16], international con-
mediate reaction requiring institution of resuscitativesensus guidelines recommend a minimum prospective
measures other than those typically used during dialysisdrug exposure experience in 1500 patients before ap-
to treat common intra-dialytic complications. Secondaryproval [20]. Priority review approval has often been
objectives were to determine the rate of all adversebased on small study populations and, thus, may lack
events following the administration of SFGC; to comparecomprehensive long-term efficacy and safety data. To
the incidence of all adverse events following SFGC andaddress these concerns, FDA requires Phase IV post-
those following placebo; to determine the incidence ofapproval studies to increase patient exposure experience,
study the effects of concomitant medications, evaluate all adverse events in SFGC-treated patients receiving
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angiotensin-converting enzyme inhibitor (ACEI) ther- ber 2 and SFGC at HD session number 3 (Fig. 1). At
hemodialysis session number 4 the patient was assessedapy as compared to patients not receiving such therapy;
for inter-dialytic adverse reactions and the study wasand to evaluate cross-reactivity to iron dextran.
completed. A single dose of 125 mg of SFGC was admin-
Patient selection istered undiluted by IV push over a period of 10 minutes.
Placebo was composed of 10 mL of bacteriostatic salinePatients were enrolled at 69 centers in the U.S. be-
(containing 9 mg/mL of benzyl alcohol) and was adminis-tween August 1999 and October 2000. All centers ob-
tered at the same rate as SFGC. Both placebo and SFGCtained approval from their respective Institutional Re-
were prepared by unblinded personnel; each syringe wasview Boards; each patient provided written informed
covered so that the personnel administering the drug andconsent. Eligible patients were adult hemodialysis pa-
reporting adverse events were blinded to the treatment.tients on chronic dialysis and supplemental epoetin ther-
Drug or placebo was administered during the first 60apy for more than 120 days. Inclusion in the study re-
minutes of the dialysis procedure. Vital signs (blood pres-quired hemoglobin13.5 g/dL, serum ferritin800 ng/mL
sure and pulse) were recorded at baseline, five minutesand transferrin saturation 50%. Patients with known
into the injection and at five and 20 minutes after comple-allergy to iron dextran were not excluded from the study.
tion of the infusion. Any adverse reaction that occurredHowever, to avoid over-enrollment of atopic or multiple
during study drug infusion was recorded and classifieddrug allergy patients, which could bias the study toward
as an instantaneous reaction, while one that occurredover-reaction, no center could enroll more than 10% of
during the ensuing dialysis session was considered anpatients with an iron dextran allergic history. This limit
immediate reaction. Before the initiation of dialysis atwas based on an estimate of a naı¨ve population rate of
the subsequent session, patients were reassessed for anyany allergy to iron dextran of less than 8% based on the
intervening adverse events, which were considered de-meta-analysis. Patients were excluded from the study if
layed reactions.they had prior treatment with SFGC, had known sensitiv-
ity to benzyl alcohol or were undergoing acute or chronic Historical iron dextran control
therapy with antihistamines or corticosteroids. Patients
Rates of reactions to iron dextran were obtained fromwho would require a first time exposure to a new type
four published studies [8–11]. These studies had similarof dialyzer membrane during the study were excluded.
designs and totaled 3768 patient exposures to differentAdditional exclusion criteria included: the recent need
iron dextran formulations (Imferon, Fisons PLC, Phar-for volume removal at an average rate of1 L/h per 70 kg
maceutical Division, Crewe, Cheshire, UK; InFeD,
patient; a Kt/V1.2 or URR65%; serum albumin3.0
Watson Pharmaceuticals Inc., Corona, CA, USA; Feri-
g/dL; repeated missed treatments during the three dex, Advanced Magnetics, Inc., Cambridge, MA, USA)
months prior to the study; signs and symptoms of, or in different patient populations (post blood loss, hemodi-
undergoing treatment for, an infectious disease; presence alysis, oncology). The validity of the historical iron dex-
of an active malignancy; suspicion or presence of unsta- tran control was confirmed by review of the actual events
ble angina; history of stroke or symptoms of cerebral included as life-threatening events in these studies. Rates
vascular insufficiency within the previous six months; of drug intolerance and life-threatening events were cal-
the inability to maintain normal oxygen saturation; any culated from these studies by three independent medical
blood glucose400 mg/dL or50 mg/dL during the two observers and the results validated by two independent
weeks prior to the study; hospitalization within 30 days biostatisticians. In Hamstra, Block and Schocket’s study
of the first hemodialysis session of the study; and any design, an event had to be documented in the medical
use of an investigational agent within seven days of the record and require medical intervention for greater than
first study session. one hour to be considered life-threatening (3/481; 0.62%)
[9]. In Fishbane et al’s study, an event had to be docu-
Study design
mented in the dialysis record and require hospitalization
Patients who satisfied the inclusion criteria and signed to be considered life-threatening (4/573; 0.70%) [8]. In
informed consent participated in the study that included the Feridex control, an event had to be life-threatening,
four sequential hemodialysis sessions. The first session characterized as an anaphylactic reaction, require inter-
consisted of screening procedures, medical history, re- vention and preclude re-exposure (11/2240; 0.49%), but
view of medications, allergy history and physical exam. suspected non-allergic events identified as acute pain
Randomization sequences were computer generated cen- with substantial hypotension requiring drug discontinua-
trally using a 1:1 ratio. At the second session, patients tion were not included as life-threatening anaphylactic
were randomized into one of two crossover treatment events [10]. In the Faich and Strobos survey of multiple
schedules: SFGC at HD session number 2 and placebo hospital discharge databases, an event required contem-
poraneous administration of iron dextran and intrave-at HD session number 3; or placebo at HD session num-
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Fig. 1. Study design.
nous epinephrine in a hospitalized dialysis patient to characteristics are summarized in Table 1 by sequence as-
be included (5/474; 1.1%) [11]. Thus, the historical iron signment. Patient demographics demonstrated a high per-
dextran reaction rate was designed to underestimate the centage of African American (58%) and Hispanic (18%)
potential life-threatening reactions from iron dextran as patients relative to the United States Renal Data System
compared to the prospective arm of the study, which patient mix, but consistent with the demographics of the
required only the subjective determination by the inves- site locations. There was no difference in demographics
tigator that the reaction was sufficiently severe to require among sequence groups or among patients who discon-
any acute immediate medical intervention beyond that tinued compared to those that completed the study.
typically provided during dialysis. Forty-four patients (44/2534; 1.7%) discontinued par-
ticipation after receiving a single study drug infusion so
Statistical methods that 2514 received SFGC and 2509 received placebo (one
The study was powered to ascertain an 80% likelihood patient inadvertently received drug at both sessions),
of identifying a 0.5% difference in life-threatening and Table 2. Of these 44, seven (0.3%) patients discontinued
drug intolerance event rates between SFGC and iron dex- participation for failure to meet continuing eligibility
tran. Confidence intervals (CIs) were constructed around criteria for drug administration at the second consecutive
both the prospective event rates and the rate from the dialysis session (for example, inadvertent self-adminis-
historical control. SFGC was to be defined as superior tration of antihistamines, discovery of an elevated trans-
to iron dextran only if there was no overlap between the ferrin saturation or serum ferritin), seventeen (0.7%)
95% CIs of the prospective life-threatening and drug patients withdrew consent during the study, and nine
intolerance event rates and that of the historical iron (0.4%) patients withdrew for various logistical reasons
dextran event rate, thus ensuring a minimum of four such as intra-study transplantation or failing to return
standard deviations between the means to establish supe- for the second consecutive hemodialysis session. Of the
riority. Additional analyses included comparison of all 44 dropouts, only eleven patients (11/2534; 0.4%) with-
adverse events between SFGC and concurrent placebo drew following adverse events. Of these 11, nine events
control using McNemar’s test, which excludes patients were deemed unrelated intercurrent events by the blinded
who react to both arms. Evaluations of cross-reactivity investigator and/or required hospitalization and thus
in prior reactors to iron dextran and the effect of concom-
study discontinuation. Of these nine, five received SFGC
itant medications (ACEI) on various reaction rates were
only (chills, pneumonia, hypertension, clotted AV fis-
performed by logistic regression analysis. Statistical sig-
tula, and fever) and four received placebo only [sepsisnificance was declared if the P value using a two-sided
(2), abdominal pain, and cholelithiasis]. Two (2/2534;Fisher’s exact test was 0.05. A FDA-mandated blinded
0.08%) discontinuations for adverse events were deemedinterim analysis was performed on the first 1106 pa-
related to study drug administration: hypotension (re-tients, assuming that all observed adverse events were
ceived SFGC only); and, abdominal pain and diarrheaattributable to SFGC. Because the double blind had not
(received placebo only).been broken, and the design remained unchanged, the
Twenty-two patients from a single site were excludedstudy continued and no statistical penalty for the interim
from analyses evaluating the study endpoints (life-threat-analysis was assessed at the final analysis of the un-
ening events, drug intolerance events, and relationship toblinded data.
iron dextran sensitivity and concomitant ACEI therapy).
During data analysis, local errors in randomization re-
RESULTS cords at that single site were discovered that could not be
corrected. These patients were not excluded from otherA total of 2534 hemodialysis patients were enrolled
in 69 dialysis centers. Their demographics and baseline analyses (all adverse events and serious adverse events).
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Table 1. Summary of patient demographics
SFGC-placebo Placebo-SFGC Total
N1264 N1270 N2534
Characteristics N (%) N (%) N (%)
Age years
MeanSD 55.7 (15.1) 56.1 (15.0) 55.9 (15.0)
Range (min–max) 19–92 19–91 19–92
Gender
Male 680 (54%) 718 (56%) 1398 (55%)
Female 584 (46%) 552 (44%) 1136 (45%)
Race
Caucasian 276 (22%) 275 (22%) 551 (22%)
Black 728 (58%) 733 (58%) 1461 (58%)
Asian-Oriental 21 (2%) 23 (2%) 44 (2%)
Hispanic 224 (18%) 227 (18%) 451 (18%)
Native American 2 (0.2%) 1 (0.1%) 3 (0.1%)
Other 13 (1%) 11 (1%) 24 (1%)
Cause of renal failure
Diabetes mellitus 431 (34%) 459 (36%) 890 (35%)
Hypertension 506 (40%) 512 (40%) 1018 (40%)
Glomerulonephritis 119 (9%) 116 (9%) 235 (9%)
Other 261 (21%) 218 (17%) 479 (19%)
Prior iron dextran exposure
Yes 1157 (92%) 1181 (93%) 2338 (92%)
No 106 (8%) 89 (7%) 195 (8%)
Table 2. Summary of patient disposition
By treatment sequence
Disposition SFGC-placebo Placebo-SFGC Total
Enrolled and included in safety analysis 1264 1270 2534
Included in outcome analysis 1254 1258 2512
By treatment
SFGC Placebo Total
Discontinuations 24 20 44
Adverse events 6 5 11
Protocol violation 2 5 7
Consent withdrawn 11 6 17
Other 5 4 9
Completed study 1240 1250 2490
Table 3. Protocol-defined adverse events: SFGC vs. placebo controlNone of these patients experienced a study endpoint
event after either placebo or SFGC. SFGC Placebo
N2493 N2487After completion of the study, one patient was diag- P value
Event N (%) (McNemar’s)nosed with acute dermal symptoms from the genetic dis-
order porphyria cutanea tarda, which the investigator Life-threatening 1 (0.04%) 0 (0%) NA
Drug intolerance 11 (0.4%) 2 (0.1%) 0.02attributed to study iron therapy. This event, identified
as a drug intolerance event, was manually re-assigned
to SFGC despite the original assignment to placebo, the
last drug received. patient each with anaphylactoid reaction, hypotension,
chills, back pain, nausea, dyspnea/chest pain, facial flush-
Drug intolerance ing, rash and cutaneous symptoms of porphyria. The two
Among SFGC treated patients, 11 (0.4%) experienced intolerance reactions following placebo were hypoten-
sion and severe gastrointestinal complaints with nausea,a reaction deemed serious enough to preclude re-expo-
sure to study drug. Among placebo treated patients, 2 itching and flushing.
There were significantly fewer drug intolerance events(0.1%) experienced such drug intolerance events (P 
0.02; Table 3). Clinical characteristics of drug intolerance in patients receiving SFGC as compared to the iron dex-
tran control (Table 4). Results of the three studies usedfollowing SFGC were: two patients with pruritus and one
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Table 4. Adverse events: SFGC vs. historical iron dextran control all adverse events was similar between SFGC (309/2514;
12.3%) and placebo (246/2509; 9.8%), the difference wasSFGC Iron dextran
Confidence
statistically significant by McNemar’s test after exclusionEvent %, N, CI intervals P value
of the 95 patients with reactions to both arms (P 
Life-threatening 0.04% 0.61% No overlap 0.0001
0.0008). The historical data for iron dextran could not1/2493 23/3768
0.00–0.22% 0.36–0.86% be analyzed for this endpoint. Overall, 5.4% of patients
Drug intolerance 0.44% 2.47% No overlap 0.0001 experienced an adverse event that was considered by
11/2493 64/2589
the investigator to be possibly related to study drug: 970.21–0.71% 1.87–3.07%
(3.9%) following SFGC and 62 (2.5%) following placeboCI denotes 95% confidence interval.
(P  0.0006).
With regard to serious adverse events, no difference
in rate between events following SFGC (14, 0.6%) andfor the historical iron dextran control demonstrated a
combined drug intolerance rate of 2.47% 0.31% (95% placebo (12, 0.5%) could be identified (P  0.8450).
Similarly, no significant relationship in serious adverseCI 1.87 to 3.07%) [8–10], whereas drug intolerance events
occurred in just 11/2493 (0.44%, 95% CI 0.21 to 0.71%, events deemed related by the investigator was identified
between SFGC (3, 0.1%) and placebo (1, 0.04%; P P  0.0001) patients receiving SFGC, thereby meeting
predefined criteria for superiority. 0.63). The three events possibly related to SFGC were
hypotension, pruritus and the previously described life-
Life-threatening reactions threatening event. The single event possibly related to
placebo was sepsis with rigors.Only one event in the study was characterized as life
threatening, and it occurred after completion of an SFGC
Adverse events by body system and type of eventinfusion. This patient had several drug allergies including
past anaphylactoid reactions to both forms of commer- The cardiovascular and digestive systems were the
only two body systems for which adverse events occurredcially available iron dextran as well as allergic reactions
to both penicillin and cephalexin. He was not on an statistically more frequently among patients receiving
SFGC as compared to placebo (P 0.05). In the cardio-ACEI. Four minutes after the SFGC infusion was com-
pleted, the patient developed severe low back pain, nau- vascular system category, 5.4% (136/2514) of SFGC-
treated patients and 4.1% (103/2509) of placebo-treatedsea and became diaphoretic. He subsequently vomited
a small amount of clear fluid and complained of shortness patients had an adverse event recorded. Within the diges-
tive system category, 64 (2.5%) of 2514 patients experi-of breath. Wheezing was noted on chest exam. Intrave-
nous diphenhydramine, intravenous hydrocortisone and enced an event following SFGC and 39/2509 (1.6%) ex-
perienced an event following placebo. Among all bodysubcutaneous epinephrine were administered between
10 and 15 minutes after drug infusion was completed systems, the COSTART preferred terms that occurred
more frequently after SFGC as compared to placeboand deemed necessary resuscitative interventions. All
symptoms resolved 20 minutes after the infusion was (P  0.05) were back pain, hypertension, dyspepsia and
nausea. Given anecdotal reports of gastrointestinal symp-completed. Hemodialysis was completed and the patient
went home on schedule without any sequelae. Since only toms following SFGC, an analysis was conducted to iden-
tify whether any combination of nausea, vomiting, diar-one patient experienced a life-threatening event during
the study, it was not possible to compare the incidence rhea, abdominal pain or hypotension occurred more
commonly following SFGC than placebo. The most com-of this event rate between SFGC and placebo (Table 3),
although confidence intervals clearly overlap. mon combination of reported events for both SFGC and
placebo was nausea and vomiting (0.6%; 15/2534). ThisThere were significantly fewer life-threatening events
in patients receiving SFGC as compared to the historical was also the only combination for which a statistically
significant difference was observed between patients re-iron dextran control (Table 4). Results of the four studies
used for the historical iron dextran control demonstrated ceiving SFGC (12/2514, 0.5%) and those receiving pla-
cebo (4/2509, 0.2%; P  0.04).a rate of life-threatening reactions of 0.61%  0.13%
(95% CI 0.36 to 0.86%) [8–11]. Life-threatening events
Hypotension; hypotension and flushingoccurred in only one of 2493 (0.04%, 95% CI 0.00 to
0.22%; P  0.0001) of patients receiving SFGC, thereby There was no significant difference in post-administra-
tion hypotensive events following SFGC (97/2514; 3.8%)meeting predefined criteria for superiority in safety.
as compared to placebo (84/2509; 3.3%; P  0.25). Of
All adverse events these, 36 patients had hypotension following both pla-
cebo and SFGC. Three episodes of combined hypoten-The percentage of patients who experienced at least
one adverse event during the study (related and unre- sion and flushing occurred during the study: two follow-
ing SFGC and one following placebo (P  0.25).lated) was 18.2% (460/2534). Although the incidence of
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Iron dextran cross-reactivity pletely resolved after 20 minutes, allowing the patient to
complete his hemodialysis treatment without the needA total of 2338 patients (92.3%) enrolled in the study
for hospitalization. This reaction would not have beenhad prior exposure to iron dextran. Sensitivity to iron
classified as life threatening in two out of the four histori-dextran was present in 144 of these patients, of which
cal iron dextran controls. Although certainly severe in34 patients had a sensitivity classified as anaphylactoid.
nature, this reaction to SFGC must be contrasted toAmong patients with previous sensitivity to iron dextran,
reactions with iron dextran, which often require hospital-the rate of serious adverse events to SFGC was 0.7%
ization and may lead to death. The drug intolerance rate(1/144) compared to 0.6% (12/2173) in patients with no
to SFGC was also statistically lower than the iron dextranprevious sensitivity (P  NS). As noted above, the only
control group. Although more drug intolerance eventslife-threatening reaction occurred in a patient with a
were seen in SFGC treated patients as compared to pla-history of multiple drug allergies including anaphylaxis
cebo, no difference in serious adverse events could beto iron dextran. The rate of all adverse events to SFGC
found. The excess events following SFGC, as comparedin patients with prior iron dextran sensitivity was 11.1%
to placebo, were predominately gastrointestinal in na-(16/144) versus 12.3% (268/2173) in patients without
ture. In contrast to an anecdotal report of the combi-such sensitivity, and logistic regression failed to show an
nation of flushing and hypotension following SFGC ad-interaction between reaction to SFGC and prior iron
ministration [26], our study found no difference in thedextran sensitivity (P  0.6957). Logistic regression also
incidence of hypotension or hypotension and flushingfailed to identify cross-reactivity between SFGC and iron
following SFGC as compared to placebo. Zanen et aldextran in either drug intolerance events or serious ad-
also postulated that oversaturation of transferrin andverse events. Of note, 127 of 144 (88%) patients with
free iron toxicity is responsible for adverse reactionsiron dextran sensitivity reported no reaction of any kind
to SFGC [26]. Transferrin saturation was not measuredfollowing SFGC administration.
immediately after SFGC administration in their study.
However, Seligman et al, using a more specific assay,Interaction with concomitant ACEI therapy
studied this issue and found that oversaturation of trans-Seven hundred and seven (707/2534; 28%) patients
ferrin did not occur after administration of 125 mg ofreceived concomitant ACEI therapy. Of these, 95 of 704
SFGC (abstract; Seligman et al, J Am Soc Nephrol 11:(13.5%) had an adverse event following SFGC and 63
297A, 2000). As recognized by others [27], the descrip-of 697 (9.0%) following placebo administration. Among
tion of transferrin oversaturation by Zanen et al [26] mostpatients without concomitant ACEI therapy, the reac-
likely resulted from the use of an invalid analytic methodtion rates were similar: 11.8% (214/1810) following
that did not differentiate between drug-bound iron andSFGC and 10.1% (183/1812) following placebo. Logistic
endogenous transferrin-bound iron (abstract; ibid).regression failed to show an interaction between con-
Treatment of iron deficiency with intravenous iron iscomitant ACEI therapy and events following SFGC as
uniquely important in the hemodialysis setting. Epoetincompared to placebo (P 0.1097). Among patients with
therapy is administered to the vast majority of theseeither suspected allergic events or drug intolerance, there
patients as treatment for anemia, with a target hemoglo-were 15 reactions following SFGC and 6 reactions fol-
bin of 11 g/dL to 12 g/dL [7]. Response to treatment islowing placebo. Among the SFGC assigned reactions,
highly variable, with iron deficiency often blunting the0.9% (6/698) occurred in patients on ACEI and 0.5%
effectiveness [17, 28]. Iron deficiency develops in most(9/1795) in patients not on ACEI. Among placebo-
hemodialysis patients, caused by persistent blood reten-assigned reactions, 0% (0/691) occurred in patients on
tion in the dialysis lines and filter, diminished dietaryACEI and 0.3% (6/1796) in patients not on ACEI. Logis-
iron absorption, and insufficient availability of circula-tic regression failed to show any relationship to incidence
tory iron during the intense erythropoietic stimulationor severity of reaction in association with concomitant
of epoetin therapy [29]. A series of studies have demon-ACEI therapy.
strated that oral iron treatment has limited efficacy com-
pared to intravenous iron in this patient population [4,
DISCUSSION 17, 30–35]. Intravenous iron therapy has emerged as a
standard of care, and the K/DOQI Anemia Clinical Prac-The results of this study demonstrate the superior
safety profile of SFGC. In comparison to iron dextran, tice Guidelines state that most epoetin-treated hemodi-
alysis patients will require intravenous iron to maintainthe drug that has been the mainstay of intravenous iron
support for hemodialysis patients in the U.S., SFGC was adequate iron stores [7]. In the last quarter of 1999, 61%
of hemodialysis patients in the United States receivedfound to be considerably safer. The rate of life-threaten-
ing reactions with SFGC compared to iron dextran was treatment with intravenous iron [6]. The primary form
of iron used for this purpose in the U.S. has been iron0.04% versus 0.61%, a reduction in risk of 93%. Further-
more, the only life-threatening reaction in this study com- dextran, an effective medication, but one associated with
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serious adverse events [8–11, 13]. Anaphylactoid reac- control group included patients that were repeatedly ex-
posed to dextran, many reactions occurred on first expo-tions have been found to occur in 0.7% [8], and serious
drug intolerance that precludes further therapy in 2.5% sure. As the studies used for the iron dextran control
included retrospective chart reviews, the incidence of re-[8–10] of the patients treated with this drug. In a study
by Fletes et al of patients experiencing an adverse event actions to iron dextran was probably underestimated. In
addition, the definition of life-threatening events in theserelated to iron dextran, 26% required emergency room
evaluation, 11% were hospitalized, and 0.6% (1/165) studies was more stringent than that used in the current
study. Although the use of a historical control is notdied [13]. Between 1976 and 1996, 31 deaths were re-
ported in the United States as a result of exposure to ideal, the studies used in the meta-analysis reported simi-
lar rates of adverse events to iron dextran and providedintravenous iron dextran [11]. In contrast, during the
same time period, no deaths were reported with SFGC an accurate reflection of the frequency of these events.
As our study demonstrates, reactions to SFGC seemuse, despite similar rates of usage [11].
Sodium ferric gluconate complex has been used in to generally be mild and self-limited, and not of the cat-
astrophic nature seen with iron dextran. An important ex-Europe for nearly four decades, and clinical studies con-
sistently demonstrated its excellent efficacy [16, 35]. How- clusion criterion in this study was the concurrent use of
antihistamines and glucocorticoids so as to maximize theever, because of the small study sizes and study designs
not focused on the evaluation of safety, little could be detection of any adverse events in the study subjects. Such
medications, especially antihistamines, are commonly givenconcluded as to the safety of SFGC from the existing
literature. SFGC was approved for use in the U.S. by to hemodialysis patients and could conceivably minimize
what were already mild reactions observed in a smallthe FDA under its priority review program in 1999. This
report represents the first published large-scale, placebo- proportion of the study subjects receiving SFGC.
An estimate of population impact of utilizing SFGCcontrolled Phase IV study devoted to safety evaluation
of a priority-reviewed drug. Drug safety evaluation in in place of iron dextran may be developed based on
the approximately 200,000 hemodialysis patients in thepatients with serious concomitant illness and polyphar-
macy, the context for priority-reviewed drugs, will often United States, and annual treatment of 61% with intrave-
nous iron [6]. The results of this study indicate a decreaserequire placebo or similarly adequate controls. Anemic
hemodialysis patients, for whom SFGC is indicated, fre- in life-threatening reactions from 0.61% with iron dex-
tran to 0.04% with SFGC, consistent with an annualquently have hypotension, gastrointestinal symptoms,
cramps, and other events that make a determination of reduction of 1140 such reactions, and a similar number of
hospitalizations. In addition, concern over the risk oftrue study drug-related events exceedingly difficult. In the
post-approval setting, an ethical argument can be made anaphylaxis with iron dextran may lead to physician re-
luctance to treat some patients who are iron deficient.that placebo controls are impermissible. Under the Dec-
laration of Helsinki, placebo or no treatment controls As a result, such patients may experience inadequately
treated anemia, with an increased risk for morbidity andare permissible only “in studies where no proven prophy-
lactic, diagnostic and therapeutic method exists” [24]. mortality resulting from inability to achieve the target
hematocrit [36–38].We believe that this single-dose, crossover study design
comports with these ethical constraints and should be Prior iron dextran exposure was present in the vast
majority (92.3%) of study subjects, reflecting the com-more widely considered to study the incidence of acute
reactions. In this study, each subject was provided active mon use of intravenous iron by the centers participating
in this study. Sensitivity to iron dextran was found totreatment and the exposure to a single dose of placebo
was clinically inconsequential. The placebo as well as occur in approximately 8% of patients exposed to iron
dextran in the historical controls used for this studystudy drug contained preservative (benzyl alcohol) so
that any reaction occurring after the study drug would [8–10]. To prevent study enrichment with highly sensi-
tized individuals, no site was permitted to enroll morebe attributed only to SFGC. While one could be tempted
to attribute the adverse reactions in the placebo phase than 10% of its subjects as iron-dextran sensitive pa-
tients. The actual study population included 144 (5.7%)to the benzyl alcohol in bacteriostatic saline, the minimal
severity and low frequency of these placebo reactions individuals sensitive to iron dextran, 34 of whom had
previously experienced dextran-related anaphylaxis. Be-would not warrant any direct evaluation of the reactions
to bacteriostatic saline compared to normal saline. cause of the severity of these reactions, it is important
to know whether such iron dextran sensitive patients alsoThe use of historical controls can be confounded by
biases, including differences in patient populations and would react with SFGC. Although iron dextran sensitive
patients were more likely to react to SFGC, they weredata collection. A historical iron dextran control was
used because of its known high event profile as well as also more likely to react to placebo. Logistic regression
analysis failed to demonstrate cross-reactivity betweenthe paucity of iron dextran naı¨ve patients in the current
U.S. hemodialysis population. Although the iron dextran SFGC and iron dextran in drug intolerance, all adverse
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events and serious adverse events. These findings empha- Post-approval safety studies should be held to the same
standards for rigorous design, review for subsequentsize the value of placebo-controlled studies. The regres-
sion analysis takes into consideration that reactions fol- publication in the medical literature, and product label-
ing as are applied to efficacy and pre-approval studies.lowing both placebo and SFGC were tenfold higher in
patients with iron dextran sensitivity. The regression Placebo controls can be used ethically in post-approval
drug studies and should be encouraged. Although theanalysis suggests that this increased reactivity is not drug-
specific. The one patient who experienced a life-threat- FDA has declined to include placebo reaction rates in
the labeling for SFGC, we suggest that such data areening reaction following SFGC had multiple drug aller-
gies, including a previous history of anaphylaxis to iron essential for physicians to identify and evaluate the true
incidence of drug-related events, particularly in patientsdextrans. Therefore, care should be used when adminis-
tering SFGC to patients with a history of severe reactions with chronic illnesses and polypharmacy, which predis-
pose to adverse events.with iron dextran or multiple drug allergies.
In a letter published in 1994, Rolla, Bucca and Brus- In conclusion, this study demonstrates that SFGC is
much safer than iron dextran. The administration of 125sino suggested that patients taking ACEI might be at
increased risk for adverse reactions during intravenous mg of SFGC over 10 minutes without a test dose may be
accomplished with few side effects. It would seem prudentiron gluconate therapy [39]. It also has been reported
that black patients, who represented 58% of the study to cease the routine use of iron dextran formulations in
hemodialysis patients. The primary use of intravenouspopulation, have a higher incidence of ACEI induced
angioedema [40]. Seven hundred and seven patients SFGC would result in a significant reduction in morbid-
ity and perhaps mortality for hemodialysis patients with(28%) in our study were receiving concomitant ACEI
therapy. For all protocol-defined adverse events, there end-stage renal disease who require parenteral iron ad-
ministration to achieve the anemia management goals de-was no significant relationship between ACEI use and
risk for reactions with SFGC. Since ACEI are commonly scribed in the K/DOQI Anemia Clinical Practice Guide-
lines [7].used for the treatment of hypertension and congestive
heart failure, it is reassuring to note that SFGC may be
safely used with this drug class. ACKNOWLEDGMENT
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